Healthtech Commercialization Blog | ARRive Growth Partners

The Reason Healthtech Founders End Up Playing Catch-Up with Commercialization

Wed, 17 Jun 2026 15:20:19 GMT

Product maturity and commercialization maturity rarely move at the same speed, and the gap between them quietly becomes one of the biggest constraints on predictable growth.

Most people in healthtech assume commercialization starts when the product is ready to scale. It actually starts much earlier than that, and most founders don't realize it until growth gets a lot harder than it should be.

I've spent more than three decades working with healthcare technology companies, and the same pattern shows up with remarkable consistency. A startup builds a compelling product, earns early traction, signs its first customers, and starts building momentum. The market is real, customers are finding value, and investors are paying attention. From the outside, the company looks ready to grow.

Then growth gets harder to sustain. Deals take longer to close, forecasts get shakier, new hires struggle to find their footing, and marketing gets busier without moving the numbers. Leadership ends up spending more time talking about growth than actually creating it. Most teams look at all of this and conclude they have a people problem, when what they really have is a commercialization problem. More specifically, they've quietly run up what I call commercialization debt.

Commercialization debt is what accumulates when a company's product maturity advances faster than its commercialization maturity, leaving growth dependent on founder effort instead of repeatable systems.

Commercialization Debt, Expanded

Commercialization debt is what accumulates when product maturity advances faster than commercialization maturity. While founders pour years into product development, customer validation, clinical workflows, integrations, security requirements, and implementation readiness, commercialization tends to develop informally on the side. Sales stays founder-driven, positioning evolves through trial and error instead of intentional design, marketing stays tactical rather than systematic, and revenue operations get built reactively rather than strategically.

None of this causes immediate problems, which is exactly why it's so easy to miss. Plenty of companies see real success despite these gaps: early customers sign, referrals create opportunities, and investors see progress. The business keeps moving forward, so the debt keeps compounding quietly underneath it.

Unlike financial debt, it never shows up on a balance sheet, and unlike a product issue, it never appears on a roadmap. So for years, founders keep operating without seeing the widening gap between how mature the product is and how mature the commercialization system needs to be to support it. Eventually that gap gets impossible to ignore.

Why Are Healthtech Companies Especially Vulnerable to It?

Every startup deals with commercialization challenges, but healthtech companies are especially exposed. Founders here are solving genuinely hard problems, navigating clinical requirements, implementation hurdles, security reviews, procurement processes, compliance considerations, stakeholder alignment, and long buying cycles all at once. Building a product that can actually serve health systems and provider organizations demands an enormous amount of focus, so product development naturally becomes the center of gravity and everything commercial becomes something to deal with later.

Sales can be formalized later, marketing can get more sophisticated later, processes can be documented later, technology can be implemented later, and operational discipline can be established later. For a while, that approach works, because the founder personally fills every one of those gaps. The founder becomes the sales process, the messaging framework, the qualification methodology, the relationship manager, and the forecasting mechanism all at once. The organization looks commercially capable, but only because one person is carrying nearly all of the commercial load. And that holds up remarkably well right up until growth expectations start to climb.

What Is the Hidden Risk of Founder-Led Growth?

Founder-led growth is often necessary in the earliest stages, and it's frequently the fastest, most effective way to reach product-market fit and land those first customers. The trouble is that it can create a false sense of commercialization readiness. A founder's ability to generate revenue doesn't mean the organization has built the systems to generate revenue consistently without them.

As long as the founder stays heavily involved, the weak spots in positioning, process, qualification, forecasting, and operational discipline stay hidden. The business keeps moving forward even though much of its success lives inside one person's head. The cracks only become visible when growth has to be handed off to the broader organization, and suddenly new salespeople need more guidance than anyone expected, marketing stops producing consistent results, pipeline quality gets erratic, forecasts get harder to trust, and customer acquisition stops feeling predictable. That's usually the moment founders start hunting for solutions, and it's also where a lot of them misdiagnose the actual problem.

Why Does Hiring More People Rarely Solve It?

When growth slows, the instinctive response is to add resources. Companies hire salespeople, bring in marketing leaders, engage agencies, invest in technology platforms, and recruit experienced executives. Those investments are often valuable and frequently necessary, but more people rarely eliminate commercialization debt. They inherit it.

Without clear positioning, even talented sales professionals struggle to tell a consistent story. Without a defined sales process, deals move through the pipeline differently depending on who owns them. Without alignment between marketing and sales, demand generation produces uneven results. And without operational discipline, forecasting stays unreliable no matter who's running the team.

That's why companies are so often blindsided when experienced hires don't deliver the results everyone expected. The problem was never a lack of talent. It was that commercialization maturity had fallen behind product maturity, and dropping new people into an immature commercialization environment doesn't create predictability. It just adds more variables to a system that was already struggling to produce consistent outcomes.

How Do the Companies That Scale Do It Differently?

The healthtech companies that scale most effectively treat commercialization as a discipline long before growth depends on it. They understand that it isn't a department, a sales function, or a marketing initiative. It's a system, one that includes positioning, demand generation, sales execution, operational discipline, technology, leadership, and organizational readiness, and it evolves alongside the product instead of waiting for a growth crisis to force its development.

Because they build that system deliberately as the company matures rather than scrambling once growth stalls, the payoff compounds in their favor: growth gets more predictable, new hires ramp faster, marketing gets more effective, forecasts get more reliable, and revenue depends less on individual heroics and more on repeatable systems.

Final Thoughts

Most healthtech startups don't hit a growth ceiling because they ran out of market, because the product lacked value, or because the team didn't work hard enough. More often, they're running into the consequences of commercialization debt. For years, product maturity advances while commercialization maturity stays tied to founder knowledge, founder relationships, and founder effort, and the organization keeps moving without noticing the imbalance growing underneath it.

Then the expectations change. Investors want predictability, teams expand, and revenue targets rise, and what used to be manageable through individual effort now has to be supported by systems. That's when the debt comes due. The founders who avoid playing catch-up aren't necessarily the ones with the best products. They're the ones who recognized that commercialization maturity deserves the same attention, discipline, and investment as product maturity. Because predictable ARR isn't the result of hiring more people. It's the outcome of building a commercialization system that consistently turns market opportunity into revenue.

See where your commercialization maturity stands.

Take the ARRive Growth Assessment to find the gaps between your product and your commercialization system before they slow you down.

Frequently Asked Questions

Why AI Didn't Replace Marketers: It Exposed Bad Systems

Thu, 11 Jun 2026 17:00:55 GMT

Somewhere right now, a founder is telling their board they don’t need marketing headcount because they have ChatGPT and a generative image tool. Maybe you’ve met this founder. Maybe you’ve been this founder. No shame. The pitch was seductive.

And for a minute, it even looked like it worked. A few prompts produced a landing page, a launch email, a hero image, a 30-second product video, and a cold outreach sequence, all before lunch. One person doing the work of an entire marketing team. The demo gods smiled.

Then the open rates flatlined. The executive at the health system or provider's office never responded. The website that looked gorgeous on launch day ranked nowhere by month three. And the product video felt off in a way nobody on the team could quite name, which is its own kind of warning sign.

This is the part the AI-everywhere keynotes skip. AI didn’t replace marketers. It exposed the founders who never had a marketing system to begin with.

Does AI Content Actually Hurt Your SEO?

Let’s start with the one number that should end the argument.

Only 6% of B2B marketers say AI tools have significantly improved their content performance, according to a 2025 MarketingProfs and Storyblok survey of more than 1,000 marketers. Six percent. After three years of “content at scale” promises, after all those LinkedIn threads about replacing your content team with a prompt library, the people actually running this stuff report almost nothing to show for it. The output went up. The performance didn’t.

of B2B marketers say AI has meaningfully improved their content performance.

MarketingProfs / Storyblok, 2025

Then Google made it personal. The March 2026 core update went after sites publishing unedited AI content at scale, and it did not go gently. The sites churning out raw machine output watched well over half their traffic evaporate, while sites built on original data and first-hand expertise held steady or gained ground. Same tools, wildly different outcomes. The variable was never the software. It was the person operating it.

And here’s the nuance that both camps get wrong, the “AI killed SEO” doomers and the “AI content is free money” bros alike. Google doesn’t penalize content for being AI-generated. Its spam policy targets thin content produced at scale with no added value, no matter who or what wrote it. When Ahrefs analyzed 600,000 ranking pages, the overwhelming majority of top results contained some AI-generated content, yet almost none were purely AI. Nearly everything ranking well was a blend, drafted by a machine and then shaped by a human who knew what good looks like.

The top of Google isn’t full of people publishing raw AI output. It’s full of people editing it. That edit is the entire job.

AI Is Only as Smart as the Hand Guiding It

Here’s where it gets specific to healthtech, and where the one-person-marketing-team fantasy really comes apart.

Selling to health systems and providers offices is a three-floor problem. Clinicians want clinical evidence. Operators want workflow impact and throughput. IT and compliance want security reviews, integration answers, and a reason to say yes that won’t get them fired. Three audiences, three languages, three different definitions of proof. And when that buying committee falls out of alignment, deals stall 68% of the time, per Sagefrog’s 2026 B2B healthcare research.

Now ask yourself which prompt fixes that. There isn’t one. There’s no system prompt for having sat in a value analysis committee meeting and watched a deal die because the messaging spoke to the CMO while the real blocker was a security questionnaire nobody answered.

Futurist Bernard Marr made this point well: the skill that matters in 2026 isn’t clever prompting, it’s judgment. Knowing when to trust AI, where it adds real value, and when a human has to take the wheel. That judgment is precisely the thing founders believe they’re replacing when they cancel the marketing hire.

Why Do AI-Generated Ads Underperform?

Generative tools will render a hero shot in 20 seconds, and that 20 seconds has convinced a lot of founders that creative is a solved problem. The data disagrees.

An NYU Stern study, fittingly titled the AI Advertising Paradox, found that when consumers know AI was involved in an ad, click-through drops roughly 31.5%, even when the ad itself is identical. Research out of Syracuse’s Newhouse School found something stranger: AI-generated ads are now nearly indistinguishable from human work, yet they consistently underperform anyway. People can’t articulate what’s wrong. They just don’t click.

The problem is rarely the model. It’s the missing creative direction. Look at how Adobe’s own design teams brief a generative tool: composition, lighting, mood, materials, brand color codes, reference imagery, technical detail. That brief is the work. Founders skip it, ship the first decent-looking render, and then wonder why everything reads slightly off. Healthcare executives notice “slightly off.” Their committees are professionally trained to.

You Cannot Vibe-Code Your Brand Home

The website story has the same shape. Most vibe-coded sites are built with modern app frameworks that draw the page inside the visitor’s browser. A human sees a slick, polished site. A search crawler, which doesn’t wait around for that drawing to happen, sees a mostly empty page where your value proposition should be. Your site can be beautiful and invisible at the same time. Plenty are.

And that’s before AEO and GEO enter the chat. Answer Engine Optimization and Generative Engine Optimization now decide whether your brand gets cited when a buyer asks ChatGPT, Perplexity, or Google’s AI Overviews who solves their problem. The old playbook doesn’t transfer cleanly either, because the sources AI engines cite are often not the ones sitting at the top of Google. Different game, different rules. And per the 2026 2X AI Visibility Index, 96% of B2B companies are invisible in AI-driven buyer discovery, surfacing only after the buyer already knows their name. At that point it isn’t discovery. It’s confirmation.

96%

of B2B companies are invisible in AI-driven buyer discovery.

2X AI Visibility Index, 2026

Your website was never a launch artifact you finish, frame, and admire. It’s a visibility engine that needs structured data behind the scenes, content that stays fresh, credible outside citations, and real depth on the topics you want to own, maintained quarter after quarter. Unglamorous plumbing, forever. Nobody vibes their way into that.

Buyers Can Tell. Executives Especially.

69% of online users say they trust AI-generated content less than human-written content, according to a Pangram Labs and YouGov survey, and the two giveaways people cite most often are replies that arrive too fast and language that sounds too formal. If that description matches anything in your sent folder, well. You see the problem.

Now scale that skepticism up to a health system executive who reads a hundred vendor emails a week and has built a career on filtering noise. In healthtech, credibility is the entire sale. AI-sounding outreach isn’t a quality issue in that market. It’s a credibility kill, and credibility doesn’t come with an undo button.

Stop guessing. Start building a system investors and healthcare organizations trust.

See how ARRive’s fractional marketing services install the commercialization engine your healthtech startup needs to achieve predictable ARR growth.

What Founders Actually Need

After all that, here’s the twist: none of this is an argument against AI. Every marketer worth hiring uses it daily. We use it to cut drafting time, compress production cycles, version creative faster, and test more than any team could a few years ago. The difference is that we use it inside a system, not instead of one.

The teams winning in 2026 aren’t the ones with the best prompts. They’re the ones with operators who know where AI belongs and where it doesn’t. They define the ICP before a single prompt gets typed. They write messaging that maps to clinical, operational, and financial outcomes, because health system committees score all three. They run integrated campaigns instead of random acts of content. And they tune a visibility engine built for both human and AI discovery, because that’s where healthtech buyers actually live now.

That’s marketing leadership. Strategic, proactive, always on. AI is a force multiplier for founders who have that system. For founders who don’t, it’s just a faster way to lose credibility they can’t buy back.

Frequently Asked Questions

About the Author

Corey Washington is VP of Marketing Operations at ARRive Growth Partners, where he helps healthtech founders build the marketing systems that turn early traction into predictable ARR. He writes about go-to-market strategy, commercialization infrastructure, and what actually works when you sell into healthcare organizations.

Why Full-Time Teams Don’t Fix Broken Commercialization in Healthtech

Mon, 08 Jun 2026 16:59:41 GMT

How early-stage healthtech founders build predictable ARR by installing a commercialization system before scaling headcount.

Key Takeaways

Most early-stage healthtech companies fail at commercialization, not at the product.
Adding full-time headcount on top of weak positioning and immature operations amplifies chaos and burns runway faster.
Fractional leadership, done right, installs systems and concentrated execution without prematurely scaling fixed overhead.
Health systems experience your company across sales, marketing, technology, and operations at the same time, so commercialization cannot run in silos.
The goal is predictability: controlled learning and repeatable execution, not maximum activity.

Healthtech founders are still being taught to scale commercialization the old way.

Raise capital. Hire full-time sales. Hire full-time marketing. Add operations. Add infrastructure. Add headcount and hope momentum follows.

The problem is that most early-stage healthtech companies do not fail because they lacked people. They fail because they scaled before the commercialization system was ready.

More people layered on top of weak positioning, disconnected messaging, unclear ownership, immature operations, inconsistent execution, and poor implementation readiness does not create predictable ARR. It amplifies chaos and burns runway faster.

That old-school mindset is the startup equivalent of printing MapQuest directions before a road trip and assuming the route will never change once you start driving.

Healthcare markets change. Buyer behavior changes. Procurement changes. Security expectations change. Technology changes. Commercialization has to evolve in real time. Yet many founders still approach growth as if headcount alone solves execution. It does not.

The Full-Time Team Myth

There is a persistent belief in startups that full-time automatically means greater accountability, stronger execution, more control, and better outcomes. It does not.

Early-stage healthtech companies often hire full-time teams before they have repeatable pipeline movement, before messaging is validated, before operational readiness exists, before implementation structure is in place, before commercialization discipline is established, and before ownership across the buyer journey is defined.

Without those elements, founders usually end up scaling activity instead of scaling results. More outbound. More campaigns. More meetings. More noise. But no predictable commercialization engine underneath it. That is where runway disappears.

Why Fractional Leadership Works When It Is Done Correctly

Fractional leadership is often misunderstood as part-time help. That is not what high-performing fractional operators are built to do.

The real value of experienced fractional leadership is concentrated execution, focused accountability, and commercialization precision without prematurely scaling fixed overhead. In the early stages, founders do not necessarily need large departments. They need experienced operators who know how to install systems, identify bottlenecks, align execution, shorten learning cycles, create operational discipline, and move opportunities toward adoption.

The goal is not to build the biggest team possible. The goal is to build a commercialization system that actually works.

Once the system is functioning, scaling becomes significantly less risky.

Commercialization Cannot Operate in Silos

One of the biggest mistakes healthtech startups make is treating commercialization as isolated functions. Sales does one thing. Marketing does another. Technology operates separately. HR and operations get brought in later.

But health systems and provider organizations do not experience your company in silos. They experience your messaging, your responsiveness, your implementation readiness, your operational maturity, your security posture, your delivery confidence, and your internal alignment all at the same time.

That is why commercialization today requires alignment across multiple operational pillars. Here is how we think about it at ARRive.

What is installed across each pillar

Sales Leadership - Pipeline discipline, opportunity progression, buyer alignment, and predictable revenue movement.

Marketing Leadership - Demand generation, positioning, messaging, trust, and measurable conversion systems.

Technology Leadership - Infrastructure, security, implementation readiness, vendor governance, and operational scalability aligned to enterprise buying expectations.

People and Operations - Organizational alignment, accountability, onboarding structure, execution cadence, and scalable operational support.

The Real Goal Is Predictability

Too many startups still operate under a see-what-sticks commercialization model. Launch campaigns. Hire quickly. Push outbound. Test random tactics. Hope something scales. That approach may create occasional wins, but it rarely creates predictable ARR.

A commercialization system should operate like a surgical approach: focused, intentional, measurable, adaptive, and disciplined.

The goal is not maximum activity. The goal is controlled learning and repeatable execution. That is what allows founders to protect runway, improve investor confidence, shorten learning cycles, scale responsibly, increase adoption predictability, and maintain leverage as the company grows.

History Repeats Itself in Healthtech

The majority of healthtech startups do not fail because the idea lacked potential. Many fail because commercialization was scaled before operational maturity existed.

Teams were hired before systems were installed. Marketing launched before positioning was clear. Sales expanded before buyer movement was understood. Operations were added after friction already existed. The result is usually the same: high activity, low predictability.

Founders who build commercialization systems before scaling headcount give themselves a far greater chance of reaching predictable ARR without sacrificing unnecessary runway along the way.

Full-time teams do not create commercialization maturity. Systems do.

See where your commercialization system stands

Take the 5 mins ARRive Growth Assessment to pinpoint the gaps across Sales, Marketing, Technology, and People before you add a single hire.

Frequently Asked Questions

ARRive Growth Partners provides fractional Sales, Marketing, Technology, and People leadership that installs the ARRive Commercialization System for healthtech founders building predictable ARR.

About the Author

Scott Heatherly is the Founder and CEO of ARRive Growth Partners, bringing 20+ years of commercialization and revenue leadership experience helping healthtech founders build predictable ARR through the ARRive Commercialization System across sales, marketing, technology, and people.

Technology Doesn’t Just Support Growth. It Signals Whether You’re Ready for It.

Fri, 15 May 2026 01:37:47 GMT

In healthtech, growth is often measured in pipeline, funding, and product progress. Technology is usually measured differently.

Uptime. Tickets. Tools. Infrastructure.

But as organizations begin to scale, a different reality emerges. Technology starts to show up in places that are far more visible:

In how confidently a buyer moves through procurement
In how quickly a deal progresses through security review
In whether delivery aligns with what was sold
In how clearly leadership can explain decisions to investors

At that point, technology is no longer operating in the background. It becomes part of how the business proves it is ready to grow.

The Shift from Systems to Strategy

Early on, technology decisions are often made with speed in mind.

What helps us build quickly
What gets us to market
What solves the immediate need

That approach works. Until the business begins to sell into more complex environments. Enterprise buyers, especially in health systems, are not just evaluating your product.

They are evaluating:

How your platform is governed
How your data is managed
How your systems will perform under pressure
How your organization makes technology decisions

This is where technology shifts from implementation to strategy.

Where Technology Directly Impacts Revenue

Series B: Complexity Multiplies

At this stage, the business is no longer small, but not yet fully structured.

Teams expand across functions and sometimes geographies
Regulatory, compliance, and clinical considerations deepen
Cross-functional execution becomes critical

This is where the absence of early HR infrastructure becomes a real constraint:

Misaligned org structures
Inefficient communication and decision-making
Compensation and leveling inconsistencies
Increasing turnover of key talent

What felt manageable at 25 people becomes a liability at 75–100.

Series C and Beyond: Scale Requires Precision

Now the expectation is predictable, repeatable growth.

Investors expect operational rigor
Leaders are measured on performance, not just potential
The cost of misalignment increases significantly

At this stage, companies often try to “install” HR quickly.

But retrofitting structure into a scaling organization is significantly harder than building it intentionally from the start.

Where Technology Directly Impacts Revenue ◢

Procurement and Security Review

There are specific moments where technology becomes a visible part of the commercial process.

Not abstractly. Directly.

Security and compliance are not side conversations. They are gating functions that answer:

Can your organization respond clearly to security questionnaires?
Are your governance practices documented and consistent?
Do your systems reflect the expectations of a health system environment?

When the answer is yes, deals move.

When the answer is unclear, timelines expand.

Executive and Board Confidence

Technology spend becomes more visible as companies grow. Boards and investors begin to ask:

What are we investing in?
Why does it matter?
How does it support revenue?

If technology decisions cannot be translated into business outcomes, confidence erodes.

Delivery and Retention

Growth does not stop at contract signature.

Can your infrastructure support onboarding at scale?
Do your systems reflect what was committed during the sale?
Is your platform resilient under real-world usage?

Technology becomes the difference between expansion and churn.

What Fractional CIO Alignment Looks Like

At a certain stage, technology needs to be managed differently. Not as a collection of systems. But as a set of deliberate, revenue-aligned decisions.

That alignment typically shows up across a few key areas:

Executive Technology Strategy

Technology decisions are tied directly to how the business grows.

Roadmaps aligned to commercial milestones and funding timelines
Architecture designed for both product delivery and customer scalability
Strategic planning that connects IT investment to revenue outcomes
Alignment between CTO and CIO functions to ensure product and infrastructure move together

Security, Compliance, and AI Governance

Enterprise buyers expect more than capability. They expect clarity and accountability.

Security and compliance practices aligned with health system expectations
AI governance frameworks that support transparency and trust
Risk assessment protocols for AI and data usage
Documentation that satisfies procurement and due diligence requirements

In many cases, this becomes a differentiator, not just a requirement.

Vendor Governance That Drives Outcomes

Technology stacks tend to grow quickly. Without discipline, they also become inefficient.

Vendor selection tied to actual business needs
Contract and cost management aligned to growth stage
Consolidation strategies that reduce redundancy
Performance tracking based on outcomes, not activity

This ensures the stack supports the business, rather than complicates it.

Budget Ownership and Board-Level Clarity

Technology investment is part of the business strategy. It should be managed that way.

Clear ownership of technology budgets
Forecasting aligned to growth scenarios
Capital and operational expense planning
Reporting that connects spend to outcomes in language boards understand

This is where technology moves from cost center to strategic lever.

Risk and Resilience as a Revenue Enabler

Reliability is often viewed as an operational concern. In healthtech, it is also a commercial one.

Business continuity and disaster recovery planning
Infrastructure designed for reliability and failover
Proactive identification of operational risk
Incident response readiness

Buyers, especially in healthcare, are evaluating whether they can trust your platform.

Resilience answers that question.

Where This Connects to ARRive ◢

At ARRive Growth Partners, technology is not positioned as a standalone function. It is part of the commercialization system.

That means:

Aligning infrastructure, security, and governance with go-to-market strategy
Supporting enterprise sales through procurement readiness
Enabling delivery through scalable systems
Providing leadership with clear, actionable visibility

The goal is not simply to implement systems. It is to ensure those systems actively support how the business sells, delivers, and grows.

Final Thought

Technology rarely determines whether a company can build. It often determines whether a company can scale. Not because of what tools are in place. But because of how clearly those tools, decisions, and systems align to the expectations of the market.

In healthtech, those expectations are high. And increasingly, they are evaluated before a contract is ever signed.

The organizations that recognize this early don’t just invest in technology. They align it.

And that alignment becomes part of how they win.

About the Author

David Jackson is the VP of IT Operations at ARRive Growth Partners, bringing 20+ years of healthcare technology leadership experience helping health-tech founders build scalable, secure technology foundations that support growth, regulatory readiness, and investor confidence.

Why HR Is a Growth Lever, Not a Support Function

Mon, 04 May 2026 19:55:00 GMT

And why it matters earlier than most health tech companies think

Most health tech companies don’t break because of product, or funding.

They break when the system behind their people can’t keep up with the pace of growth.

In a category where commercialization is complex: long sales cycles, regulatory pressure, clinical validation, multi-stakeholder buyers. But execution and delivery isn’t optional. It’s everything.

And yet, one of the most critical systems for execution is often introduced too late:

HR.

The Hidden Risk Across Every Stage of Growth

What’s often misunderstood is that people challenges don’t start at scale.

They start early, and compound quietly.

Seed Stage: Speed Without Structure

At the earliest stages, health tech companies are building quickly:

Founders are hiring fast, often through networks
Roles are loosely defined and constantly evolving
There’s little distinction between “what we need now” vs. “what we need next”

This works, until it doesn’t.

Early misalignment in roles, expectations, and hiring profiles becomes harder (and more expensive) to unwind later.

Series A: Growth Starts to Expose Gaps

Now there’s capital. Expectations increase.

Hiring accelerates across product, GTM, and operations
Managers emerge, often without support or training
Compensation decisions become more visible, and more scrutinized

Without a people system in place, companies start to feel friction:

Inconsistent hiring outcomes
Early performance issues with no clear framework to address them
Leadership teams spending time managing people problems instead of scaling the business

Series B: Complexity Multiplies

At this stage, the business is no longer small, but not yet fully structured.

Teams expand across functions and sometimes geographies
Regulatory, compliance, and clinical considerations deepen
Cross-functional execution becomes critical

This is where the absence of early HR infrastructure becomes a real constraint:

Misaligned org structures
Inefficient communication and decision-making
Compensation and leveling inconsistencies
Increasing turnover of key talent

What felt manageable at 25 people becomes a liability at 75–100.

Series C and Beyond: Scale Requires Precision

Now the expectation is predictable, repeatable growth.

Investors expect operational rigor
Leaders are measured on performance, not just potential
The cost of misalignment increases significantly

At this stage, companies often try to “install” HR quickly.

But retrofitting structure into a scaling organization is significantly harder than building it intentionally from the start.

Where HR Fits in the ARRive System ◢

At ARRive Growth Partners, we view growth as an interconnected system.

Commercialization and growth looks at how the entire organization executes consistently.

That includes:

Who you hire
How teams are structured
How performance is defined and measured
How leaders make decisions and drive accountability

HR, when done right, is not a support function within that system.

It’s an enabler of it.

Why Bringing in HR Earlier Changes the Outcome

When HR is embedded earlier - alongside go-to-market, operations, and technology - it creates leverage across every part of the business:

Hiring becomes intentional → aligned to actual business outcomes, not urgency
Managers are equipped earlier → reducing downstream performance issues
Compensation is structured → supporting equity, retention, and scalability
Performance is measurable → not subjective or reactive
Execution becomes repeatable → not dependent on a few high performers

This doesn’t slow companies down, but rather it allows them to scale faster, without breaking what’s already working.

Why This Matters Specifically in Health Tech

Health tech operates under a different level of pressure:

Regulatory environments require precision and documentation
Clinical and non-clinical teams must work in sync
Sales cycles are longer, more complex
Talent is highly specialized and highly competitive

You’re not just building a company. You’re building a system that needs to perform under scrutiny.

Without a strong people foundation:

Hiring mistakes are more costly
Misalignment between teams slows commercialization
Leadership bandwidth is consumed by internal friction
Growth becomes harder to sustain - even with strong demand

The Role of Embedded HR Leadership

This is where my role comes in.

As part of the ARRive ecosystem, I’m not operating as a standalone HR function.

I’m working within the broader commercialization strategy, ensuring the people system supports how the business actually grows.

Over the past 20+ years, I’ve worked inside and alongside growing companies, from early-stage teams building from the ground up to organizations scaling through Series B, C, and beyond.

I’ve seen firsthand where growth accelerates, and where it breaks:

Hiring too quickly without clarity on success profiles
Managers promoted without support or expectations
Compensation decisions made in isolation, creating long-term inequities
Performance managed reactively instead of systematically

And more importantly, I’ve built the systems that fix it, before it becomes a constraint.

That means:

Aligning hiring with go-to-market and operational priorities
Designing org structures that support execution—not just headcount
Building performance systems that match the stage of the company
Creating clarity for leaders so they can focus on scaling, not troubleshooting

It’s not about “adding HR.”

It’s about ensuring the system behind your people is built to scale alongside the rest of the business.

Final Thought

Most health tech companies don’t realize they needed HR earlier until they’re already feeling the impact.

Missed hiring targets.
Manager inconsistency.
Turnover in key roles.
Execution gaps across teams.

By that point, the work becomes reactive.

The opportunity, especially in health tech, is to build the people system early enough that growth doesn’t outpace it.

Because the companies that scale best, are investing in the system that allows all of it to work together.

About the Author

Lindsay Dagiantis is the VP People & HR Services at ARRive Growth Partners, bringing 20+ years of experience building and scaling people operations for growth-stage companies.

Healthtech Founders: Don’t Hire for Busywork. Hire for a Success System.

Fri, 03 Oct 2025 16:58:43 GMT

In healthtech, one bad commercial hire doesn’t just slow you down - it can quietly erase 6–12 months of runway. I’ve seen it across multiple startups, hiring everyone from marketers and SDRs to content specialists and publicists.

The pattern was clear:

Candidates came in unprepared and too casual for enterprise sales.
Resumes checked maybe half the boxes of what was actually needed.
Answers felt scripted; prospect pools were thin.

When I asked the only question that matters, “What is your process?” the answers were checklists:

“I clear emails, search for prospects, update the CRM, then make calls…”

That is not a process. That is activity. And activity burns runway.

The Question That Separates Pros From Pretenders

A real sales or marketing leader can walk you through their system for creating a predictable pipeline and accurate forecasts. If they cannot, you will be stuck coaching them while your timeline to scale disappears.

Here's the two hard truths:

You cannot hire your way to market fit.
Sales and marketing running in silos will never produce predictable ARR.

What a Real Success System Looks Like

Here is what I expect when someone explains their process:

ICP Precision + One Story: A single ICP, one narrative, and persona-specific messaging used across SDR, AE, and marketing.
Evidence Early: Clinical outcomes, ROI, and security/IT proof before the first meeting, not after.
Stage-Gated Commercialization: Clear exit criteria from interest → evidence → consensus → procurement → signature → expansion.
Operating Cadence: Weekly pipeline hygiene, leading indicators (meetings by persona, conversion rates, cycle time), not vanity MQLs.
Forecast Discipline: Bottom-up commitment based on buyer consensus, not seller hope.
Rules of Engagement: SDR/BDR orchestrated with AEs. Marketing drives demand creation and enablement.
Conference ROI Guardrails: No $50k booths without meeting SLAs and post-show follow-through.

Bottom Line: If a candidate cannot describe specifics like this, especially with experience in a health system environment, move on.

Why ARRive Growth Partners Exists

These failures are exactly why I built ARRive Growth Partners. We bring fractional sales and marketing leadership into healthtech startups and install a structured, stage-gated commercialization system called the Healthtech ARR Flywheel.

Our model:

Diagnose: Analyze ICP, deal history, and workflows to uncover breakdowns and stalled cycles.
Align: Establish one story across SDRs, AEs, and Marketing with mapped persona touchpoints.
Package Evidence: Build proof packs by persona (clinical, ROI, security/IT ) .
Orchestrate: Run stage-gated plays with exit criteria and meeting SLAs.
Compress Timelines: Map procurement steps (BAA/MSA/InfoSec) upfront to avoid surprises.
Predict + Expand: Drive disciplined forecasting and land-and-expand motions.

The Outcome: founders protect runway, investors regain confidence, and ARR becomes forecastable, not accidental.

A Quick Scorecard You Can Use Tomorrow

Ask every candidate, full-time or fractional:

Walk me through your stage-gated commercialization model for health systems.
Show your persona-specific evidence pack (clinical, ROI, security).
How do you prove ICP fit and avoid opportunistic detours?
What exit criteria must be met before moving a deal forward?
How do you structure SDR/AE/Marketing handoffs?
What leading indicators predict your quarter?
How do you shorten BAA/MSA/InfoSec cycles?
Share a forecast miss and the process change that followed.
What are your conference ROI rules?
Show enablement examples that actually shortened cycles.

If they cannot answer these clearly, they do not have a system.

Bottom Line

Do not hire for activity. Do not hire for “busywork.” Hire for a success system, or install one first. That is where ARRive Growth Partners starts.